Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07374848 · ClinicalTrials.gov registry record · Phase 1

Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

A Phase 1 study of Solid Tumors and Sarcomas, sponsored by Zai Lab (Shanghai) Co..

Recruiting
Registry status
Phase 1
Development phase
180
Enrollment target
2
Study locations

NCT07374848 is a Phase 1 study of Solid Tumors and Sarcomas that is actively recruiting participants, run by Zai Lab (Shanghai) Co.. The registered enrollment target is 180 participants, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (36% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07374848, a Phase 1 study of Solid Tumors and Sarcomas, is actively recruiting participants, sponsored by Zai Lab (Shanghai) Co..

RECRUITING
Registry status
Phase 1
Development phase
180 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.

Conditions Studied

Interventions

  • DRUG ZL-6201

Study Locations (2)

Florida

  • Zai Lab Site 02026 - Sarasota

Virginia

  • Zai Lab Site 02006 - Fairfax

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2026-03
Est. Completion 2029-09
Phase Phase 1

Sponsor

Zai Lab (Shanghai) Co.

5 total trials

What the Registry Record Tells You About NCT07374848

The ClinicalTrials.gov registry entry for NCT07374848 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (36% lower). The listed sponsor is Zai Lab (Shanghai) Co., which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which ZL-6201 is the first listed.

NCT07374848 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Virginia.

Frequently Asked Questions

What is clinical trial NCT07374848 about?

NCT07374848 is a clinical study titled "Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors". The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.

What is the current status of trial NCT07374848?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2026-03. Estimated completion is 2029-09.

What conditions does trial NCT07374848 study?

This clinical trial studies the following conditions: Solid Tumors, Sarcomas.

What interventions are being tested in trial NCT07374848?

The interventions under investigation include: ZL-6201 (DRUG).

Who is sponsoring clinical trial NCT07374848?

This trial is sponsored by Zai Lab (Shanghai) Co., which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07374848 being conducted?

This trial has 2 study locations across Florida, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.